ClinicalTrials.gg
CompletedNCT03429543Updated Feb 23, 2024Results posted

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

A Phase 3 interventional study of Metformin and Insulin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 83 sites in 14 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
34th of 67
175 · median 175
Started
2018
the only one that year
Phase 3
31 of 67
none open now
Registered
58th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment, is the only one that started in 2018, is one of 31 in phase 3, and was the 58th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking metformin, insulin or both drugs (DINAMO TM) or who are treatment naïve or not on active treatment after metformin withdrawal (DINAMO TM MONO) .

Empagliflozin and linagliptin are both approved for use in adult patients with type 2 diabetes. This study will assess how well empagliflozin and linagliptin work by finding out how these treatments affect blood glucose (sugar) levels compared to placebo (a pill that contains no active drug), in children and adolescents. Empagliflozin and linagliptin are considered investigational products in this study since while they have been approved for use in adults, they have not been approved for children and adolescents due to lack of clinical studies in this specific population.

Patients with type 2 diabetes have higher levels of blood glucose (sugar) than patients who do not have this disease. The high level of sugar in the blood can lead to serious short-term and long-term medical problems. The main goal of treating diabetic patients is to lower blood glucose to a normal level. Lowering and controlling blood glucose help prevent or delay complications of diabetes such as heart disease, kidney, eye and nerve diseases, and the possibility of amputation.

Empagliflozin is a drug that helps to reduce blood glucose (sugar) levels by causing glucose to be excreted in the urines.

Linagliptin works by increasing the production of insulin (a hormone that controls the level of blood glucose) after meals when blood glucose (sugar) levels are too high. This helps to lower blood sugar levels.

The subject will either receive one of the active study drugs or a placebo. This study will be double blind; this means that neither the subject, nor the study doctor will know which treatment the subject will receive.

Which treatment the subject receives is decided by a computer, purely by chance; this is called a "random assignment".

For this study, there will first be a screening visit, followed by a 2-week placebo run-in period (all subjects will take placebo once daily). This run-in period is designed to ensure subjects are able to take the study drugs as described in the study protocol. Thereafter there will be a 26-week treatment phase (week 1-week 26) and a 26-week safety extension period (week 27-week 52). Following this there will be a follow-up visit at week 55.

On Day 1 after the placebo run-in phase, the subject will be randomly assigned to receive one of the 3 treatments: empagliflozin 10 mg, linagliptin 5 mg or placebo in a blinded manner. This treatment will continue up to week 14. Then after week 14, the subject will be assigned to receive one of the following 4 treatments: empagliflozin 10 mg, empagliflozin 25 mg, linagliptin 5 mg or placebo in a blinded manner. The drugs assigned after week 14 will be the same drugs as on Day 1 but some subjects will receive a higher dose of empagliflozin.

After the completion of the 26-week treatment period, the subject will enter a 26-week safety extension period. The same active treatment that the subject had been assigned to at week 14 visit will be continued. Subjects assigned to placebo on Day 1 will be randomly assigned to receive one of the 3 active treatments: empagliflozin 10 mg, empagliflozin 25 mg or linagliptin 5 mg in a blinded manner. This safety extension period is primarily designed to provide additional information on how well empagliflozin and linagliptin are tolerated.

Following the treatment phases, there will be a follow-up visit at week 55

Intervention model description:

Eligible subjects with HbA1c of 6.5% to 10.5% at screening will be randomized in a 1:1:1 ratio to receive empagliflozin 10 mg, linagliptin 5 mg or placebo. HbA1c assessment will be performed at Week 12. All subjects with Week 12 HbA1c \< 7% will remain on previously assigned randomized treatment. Subjects taking empagliflozin with Week 12 HbA1c >= 7% will be re-randomized in a 1:1 ratio to continue on the low dose treatment (empagliflozin 10 mg) or up-titrate to the high dose treatment (empagliflozin 25 mg). Subjects taking linagliptin or placebo with Week 12 HbA1c >= 7% will remain on previously assigned treatment. All subjects will get new medication kits dispensed at Week 14 to maintain the blinding.

At Week 26, all subjects previously assigned to placebo will be re-randomized in a 1:1:1: ratio to receive one of the active treatments: empagliflozin 10 mg, empagliflozin 25 mg or linagliptin 5 mg. All subjects will get new medication kits dispensed at Week 14 to maintain the blinding.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 10 to 17 years (inclusive) at the time of randomisation (Visit 2)
  • Male and female patients
  • Women of (WOCBP) must be ready and able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient's legal representative information sheet.
  • Signed and dated written provided by the patient's parent(s) (or legal guardian) and patient's assent in accordance with ICH-GCP and local legislation prior to admission to the trial (informed assent will be sought according to the patient's age, level of maturity, competence and capacity)
  • Documented diagnosis of T2DM at Visit 1A:

    • DINAMO TM: Documented diagnosis of T2DM for at least 8 weeks at Visit 1A
    • DINAMO TM Mono: Confirmation of T2DM at Visit 1A
  • Insufficient glycaemic control as measured by the central laboratory at Visit 1A:

    • DINAMO TM: ≥ 6.5% and ≤ 10.5%
    • DINAMO TM Mono: HbA1c ≥ 6.5% and ≤ 9.0%
  • DINAMO TM: Patients treated with

    • diet and exercise plus metformin at a stable dose for 8 weeks prior to Visit 2 or not tolerating metformin (defined as patients who were on metformin treatment for at least 1 week and had to discontinue metformin due to metformin-related side effects as assessed by the investigator) AND/OR
    • diet and exercise plus stable basal or MDI insulin therapy,, defined as a weekly average variation of the basal insulin dose ≤ 0.1 IU/kg over 8 weeks prior to Visit 2. - DINAMOTM Mono: Drug-naïve patients or patients not on active treatment (including discontinuation of metformin due to intolerance [or previous discontinuation for other reasons] and/or discontinuation of insulin [insulin use must be 8 weeks or less] at investigator's discretion) prior to or at Visit 1A)
  • ≥ 85th percentile for age and sex according to WHO references at Visit 1B
  • Non-fasting serum C-peptide levels ≥ 0.6 ng/ml as measured by the central laboratory at Visit 1A
  • Compliance with trial medication intake must be between 75% and 125% during the open-label placebo run-in period
  • Further inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Any history of acute metabolic decompensation such as diabetic ketoacidosis within 8 weeks prior to Visit 1A and up to randomisation (mild to moderate polyuria at the time of randomisation is acceptable)
  • Diagnosis of monogenic diabetes (e.g. MODY)
  • History of pancreatitis
  • Diagnosis of metabolic bone disease
  • Gastrointestinal disorders that might interfere with study drug absorption according to investigator assessment
  • Secondary obesity as part of a syndrome (e.g. Prader-Willi syndrome)
  • Any antidiabetic medication (with the exception of metformin and/or insulin background therapy) within 8 weeks prior to Visit 1A and until Visit 2
  • Treatment with weight reduction medications (including anti-obesity drugs) within 3 months prior to Visit 1A and until Visit 2
  • History of weight-loss surgery or current aggressive diet regimen (according to investigator assessment) at Visit 1A and until Visit 2
  • Treatment with systemic for > 1 week within 4 weeks prior to Visit 1A and up to Visit 2 Inhaled or topical use of corticosteroids (e.g. for asthma/) is acceptable.
  • Change in dose of thyroid hormones within 6 weeks prior to Visit 1A or planned change or initiation of such therapy before Visit 2
  • Known or allergy to the products or their
  • Impaired renal function defined as estimated (eGFR) \< 60 ml/min/1.73m² (according to Zappitelli formula) as measured by the central laboratory at Visit 1A
  • Indication of liver disease defined by serum level of either (ALT), aspartate transaminase (AST) or alkaline phosphatase above 3 fold (ULN) at Visit 1A as measured by the central laboratory at Visit 1A
  • History of belonephobia (needle phobia)
  • Any documented active or suspected or history of malignancy within 5 years prior to Visit 1A, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix
  • Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells (e.g. malaria, babesiosis, haemolytic anaemia)
  • Any other acute or chronic medical or psychiatric condition or laboratory abnormality that, based on investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome
  • Medical to metformin according to the local label (for patient on metformin background therapy)
  • Patient not able or cannot be supported by his/her parent(s) or legal guardian to understand and comply with study requirements based on investigator's judgement
  • Previous randomisation in this trial
  • Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s)
  • Chronic alcohol or drug abuse within 3 months prior to Visit 1A or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial
  • Female patients who are pregnant, nursing, or who plan to become pregnant in the trial
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
175 participants (actual)

Study arms

  • Placebo comparator
    Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ Mono

    Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily, until end of treatment.

    Drug: Metformin · Drug: Insulin · Drug: Placebo

  • Experimental
    Placebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono

    Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily, until end of treatment.

    Drug: Metformin · Drug: Insulin · Drug: Placebo · Drug: Linagliptin

  • Experimental
    Placebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono

    Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 10 milligram (mg) empagliflozin, taken once daily, until end of treatment.

    Drug: Metformin · Drug: Insulin · Drug: Placebo · Drug: Empagliflozin

  • Experimental
    Placebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono

    Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily. At week 26, patients were re-randomised to receive 25 milligram (mg) empagliflozin, taken once daily, until end of treatment.

    Drug: Metformin · Drug: Insulin · Drug: Placebo · Drug: Empagliflozin

  • Experimental
    Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono

    Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 5 milligram (mg) Linagliptin once daily, until end of treatment.

    Drug: Metformin · Drug: Insulin · Drug: Linagliptin

  • Experimental
    Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono

    Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily, until Week 14. Responder patients were not re-randomised at week 14 and continued 10 mg empagliflozin, taken once daily, until end of treatment. Non responder patients were re-randomised at Week 14 to receive 10 mg empagliflozin, taken once daily, until end of treatment.

    Drug: Metformin · Drug: Insulin · Drug: Empagliflozin

  • Experimental
    Empagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono

    Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily until Week 14. Non responder patients were re-randomised at Week 14 to receive 25 mg empagliflozin, taken once daily, until end of treatment.

    Drug: Metformin · Drug: Insulin · Drug: Empagliflozin

Interventions

  • At least 1000 mg/day or up to a maximal tolerated dose.

  • Basal or multiple dose injection.

  • DrugPlacebo

    1 film-coated tablet of either Linagliptin or Empagliflozin matched placebo once daily.

  • 1 film-coated tablet Linagliptin once daily, until end of treatment.

    Also known as: Trajenta(R)

  • 1 film-coated tablet of Empagliflozin once daily, until end of treatment.

    Also known as: Jardiance(R)

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ

    Adjusted means taken from the following three models, as pre-specified in the protocol: Treatment group 1 (TG1): \[Placebo\], \[Linagliptin 5mg\] and \[Empagliflozin pooled\] Treatment group 2 (TG2): \[Placebo\] and \[Empagliflozin 10mg and 10+25mg\] Treatment group 3 (TG3): \[Placebo\] and \[Empagliflozin 10mg\] ANCOVA with continuous covariate (baseline HbA1c) and categorical covariates (treatment \& age). Effect of linagliptin and of empagliflozin was compared with placebo at an overall α of 0.05 (2-sided) using the Hochberg method to account for multiple testing. After having obtained statistically significant results for both hypotheses of the primary family of hypotheses (TG1), the secondary hypotheses were to compare the individual empagliflozin doses versus placebo (TG2 \& TG3). ANCOVA utilized a weight of zero for patients who were not in the hypothesis test of interest, a value of 2 for re-randomised patients who were in the hypothesis test of interest and a value of 1 otherwise.

    Time frame: Baseline (Day 1) and week 26 of treatment.

  2. Percentage of Patients With Treatment Failure up to or at Week 26

    Percentage of patients with treatment failure up to or at Week 26 as a binary endpoint, defined as meeting at least one of the following criteria: * Use of rescue medication at any time up to Week 26 * Increase from baseline in HbA1c by 0.5% at Week 26 . Increase from baseline in HbA1c to above 7.0% at Week 26 in patients with baseline HbA1c \<7.0%

    Time frame: Up to 26 weeks.

Secondary outcomes

  1. Change in HbA1c (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ Mono

    Change in Glycated haemoglobin (HbA1c) (%) from baseline to the end of 26 weeks. Adjusted values came from a restricted maximum likelihood (REML) approach with mixed model for repeated measures (MMRM). Analyses included fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as the repeated measure with an unstructured covariance structure used to model the within-patient measurements.

    Time frame: Baseline (Day 1) and week 26 of treatment.

  2. Time to Treatment Failure

    Time to treatment failure was analysed by Kaplan-Meier estimates up to the end of the study (Week 52). Patients in the placebo group were censored after 26 weeks unless a prior treatment failure was observed.

    Time frame: Up to 395 days.

  3. Change in Fasting Plasma Glucose (FPG, mg/dL) From Baseline to the End of 26 Weeks

    Change in fasting plasma glucose (FPG, Milligrams Per Deciliter (mg/dL)) from baseline to the end of 26 weeks. Adjusted values taken from analysis of covariance (ANCOVA) model with treatment as a fixed classification effect, baseline FPG as linear covariate and age at randomisation as categorical covariate. The random error was assumed to be normally distributed.

    Time frame: Baseline (Day 1) and week 26.

  4. Change in Body Weight (kg) From Baseline to the End of 26 Weeks

    Change in body weight (kg) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.

    Time frame: Baseline (Day 1) and week 26.

  5. Change in Systolic Blood Pressure (SBP, mmHg) From Baseline to the End of 26 Weeks

    Change in systolic blood pressure (SBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.

    Time frame: Baseline (Day 1) and week 26.

  6. Change in Diastolic Blood Pressure (DBP, mmHg) From Baseline to the End of 26 Weeks

    Change in diastolic blood pressure (DBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.

    Time frame: Baseline (Day 1) and week 26.

  7. Percentage of Patients Who Achieve HbA1c <6.5% at the End of 26 Weeks

    Percentage of patients who achieve HbA1c \<6.5% at the end of 26 weeks.

    Time frame: Baseline (Day 1) and week 26.

  8. Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks

    Percentage of patients who achieve HbA1c \<7.0% at the end of 26 weeks.

    Time frame: Baseline (Day 1) and week 26.

07

Results

Posted Feb 23, 2024

Participant flow

This study was a randomised, placebo-controlled, double-blind, and parallel group trial with 3 treatment arms (placebo, 5 mg linagliptin, 10 mg empagliflozin). The main trial DINAMOᵀᴹ consisted of patients treated with metformin and/or insulin or patients who do not tolerate metformin. The ancillary trial DINAMOᵀᴹ Mono consisted of treatment-naïve patients or patients not on active treatment.

Participant flow — Overall Study
MilestonePlacebo - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ Mono
Started7191616594513
Treated7191616584513
Completed0171514473612
Not completed72121291
Withdrew: Adverse event1100020
Withdrew: Lost to follow-up1000100
Withdrew: Withdrawal by subject5012631
Withdrew: Other reason than listed0100440
Withdrew: Not treated0000100

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ

Adjusted means taken from the following three models, as pre-specified in the protocol: Treatment group 1 (TG1): \[Placebo\], \[Linagliptin 5mg\] and \[Empagliflozin pooled\] Treatment group 2 (TG2): \[Placebo\] and \[Empagliflozin 10mg and 10+25mg\] Treatment group 3 (TG3): \[Placebo\] and \[Empagliflozin 10mg\] ANCOVA with continuous covariate (baseline HbA1c) and categorical covariates (treatment \& age). Effect of linagliptin and of empagliflozin was compared with placebo at an overall α of 0.05 (2-sided) using the Hochberg method to account for multiple testing. After having obtained statistically significant results for both hypotheses of the primary family of hypotheses (TG1), the secondary hypotheses were to compare the individual empagliflozin doses versus placebo (TG2 \& TG3). ANCOVA utilized a weight of zero for patients who were not in the hypothesis test of interest, a value of 2 for re-randomised patients who were in the hypothesis test of interest and a value of 1 otherwise.

Time frame:
Baseline (Day 1) and week 26 of treatment.
Reported as:
Least squares mean · Percent change
Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ
Percent changePlacebo - DINAMOᵀᴹ (TG1, TG2 & TG3)Linagliptin 5 mg - DINAMOᵀᴹ (TG1)Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ (TG1)Empagliflozin 10 mg - DINAMOᵀᴹ (TG3)Empagliflozin 10 mg - DINAMOᵀᴹ & Empagliflozin 10 - 25 mg - DINAMOᵀᴹ (TG2)
Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹNA (NA to NA)0.33 (-0.13 to 0.79)-0.17 (-0.64 to 0.31)-0.49 (-1.03 to 0.04)0.14 (-0.42 to 0.71)
Statistical analysis
  • Placebo - DINAMOᵀᴹ (TG1, TG2 & TG3) vs Linagliptin 5 mg - DINAMOᵀᴹ (TG1) · ANCOVA · p = 0.2935 · Mean difference (final values): -0.34 · 95% CI -0.99 to 0.30Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ (TG1, TG2 & TG3) vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ (TG1) · ANCOVA · p = 0.0116 · Mean difference (final values): -0.84 · 95% CI -1.50 to -0.19Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ (TG1, TG2 & TG3) vs Empagliflozin 10 mg - DINAMOᵀᴹ & Empagliflozin 10 - 25 mg - DINAMOᵀᴹ (TG2) · ANCOVA · p = 0.1943 · Mean difference (final values): -0.52 · 95% CI -1.31 to 0.27Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ (TG1, TG2 & TG3) vs Empagliflozin 10 mg - DINAMOᵀᴹ (TG3) · ANCOVA · p = 0.0015 · Mean difference (final values): -1.18 · 95% CI -1.90 to -0.45Mean difference calculated as \[Treatment\] - Placebo.
PrimaryPercentage of Patients With Treatment Failure up to or at Week 26

Percentage of patients with treatment failure up to or at Week 26 as a binary endpoint, defined as meeting at least one of the following criteria: * Use of rescue medication at any time up to Week 26 * Increase from baseline in HbA1c by 0.5% at Week 26 . Increase from baseline in HbA1c to above 7.0% at Week 26 in patients with baseline HbA1c \<7.0%

Time frame:
Up to 26 weeks.
Reported as:
Number · Percentage of subjects
Percentage of Patients With Treatment Failure up to or at Week 26
Percentage of subjectsPlacebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Percentage of Patients With Treatment Failure up to or at Week 2660.0 (18.9 to 92.4)50.0 (15.3 to 84.7)50.0 (15.3 to 84.7)
Statistical analysis
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · Fisher Exact · p = 1.0000 · Risk difference (rd): -10.0 · 90% CI -58.7 to 43.7Risk difference calculated as \[treatment\]-\[placebo\].
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · Fisher Exact · p = 1.0000 · Risk difference (rd): -10.0 · 90% CI -58.7 to 43.7Risk difference calculated as \[treatment\]-\[placebo\].
SecondaryChange in HbA1c (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ Mono

Change in Glycated haemoglobin (HbA1c) (%) from baseline to the end of 26 weeks. Adjusted values came from a restricted maximum likelihood (REML) approach with mixed model for repeated measures (MMRM). Analyses included fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as the repeated measure with an unstructured covariance structure used to model the within-patient measurements.

Time frame:
Baseline (Day 1) and week 26 of treatment.
Reported as:
Least squares mean · Percent change
Change in HbA1c (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ Mono
Percent changePlacebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Change in HbA1c (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ Mono0.15 (-1.45 to 1.75)-0.53 (-2.01 to 0.95)-0.23 (-1.83 to 1.37)
Statistical analysis
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · Mixed Models Analysis · p = 0.4828 · Adjusted mean difference: -0.68 · 95% CI -2.86 to 1.49Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · Mixed Models Analysis · p = 0.7047 · Adjusted mean difference: -0.38 · 95% CI -2.64 to 1.88Mean difference calculated as \[Treatment\] - Placebo.
SecondaryTime to Treatment Failure

Time to treatment failure was analysed by Kaplan-Meier estimates up to the end of the study (Week 52). Patients in the placebo group were censored after 26 weeks unless a prior treatment failure was observed.

Time frame:
Up to 395 days.
Reported as:
Mean · Days
Time to Treatment Failure
DaysPlacebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Time to Treatment Failure65.600 ± 19.94172.167 ± 20.280167.333 ± 26.711
Statistical analysis
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · Log Rank · p = 0.8626
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · Log Rank · p = 0.2827
SecondaryChange in Fasting Plasma Glucose (FPG, mg/dL) From Baseline to the End of 26 Weeks

Change in fasting plasma glucose (FPG, Milligrams Per Deciliter (mg/dL)) from baseline to the end of 26 weeks. Adjusted values taken from analysis of covariance (ANCOVA) model with treatment as a fixed classification effect, baseline FPG as linear covariate and age at randomisation as categorical covariate. The random error was assumed to be normally distributed.

Time frame:
Baseline (Day 1) and week 26.
Reported as:
Least squares mean · Milligrams Per Deciliter (mg/dL)
Change in Fasting Plasma Glucose (FPG, mg/dL) From Baseline to the End of 26 Weeks
Milligrams Per Deciliter (mg/dL)Placebo - DINAMOᵀᴹLinagliptin 5 mg - DINAMOᵀᴹEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹPlacebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Change in Fasting Plasma Glucose (FPG, mg/dL) From Baseline to the End of 26 Weeks15.70 (-0.53 to 31.93)10.29 (-6.12 to 26.69)-19.48 (-36.39 to -2.57)-38.50 (-62.67 to -14.33)0.12 (-23.67 to 23.91)-18.45 (-40.00 to 3.10)
Statistical analysis
  • Placebo - DINAMOᵀᴹ vs Linagliptin 5 mg - DINAMOᵀᴹ · ANCOVA · p = 0.6438 · Mean difference (final values): -5.41 · 95% CI -28.49 to 17.67Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ · ANCOVA · p = 0.0035 · Mean difference (final values): -35.18 · 95% CI -58.61 to -11.74Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · ANCOVA · p = 0.0310 · Mean difference (final values): 38.62 · 95% CI 4.54 to 72.70Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · ANCOVA · p = 0.1994 · Mean difference (final values): 20.05 · 95% CI -13.01 to 53.11Mean difference calculated as \[Treatment\] - Placebo.
SecondaryChange in Body Weight (kg) From Baseline to the End of 26 Weeks

Change in body weight (kg) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.

Time frame:
Baseline (Day 1) and week 26.
Reported as:
Least squares mean · kilogram (kg)
Change in Body Weight (kg) From Baseline to the End of 26 Weeks
kilogram (kg)Placebo - DINAMOᵀᴹLinagliptin 5 mg - DINAMOᵀᴹEmpagliflozin Pooled (10 mg and 25 mg)Placebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Change in Body Weight (kg) From Baseline to the End of 26 Weeks-0.04 (-1.40 to 1.32)1.42 (0.04 to 2.81)-0.79 (-2.17 to 0.59)2.64 (-0.35 to 5.63)2.69 (0.24 to 5.14)1.29 (-1.75 to 4.33)
Statistical analysis
  • Placebo - DINAMOᵀᴹ vs Linagliptin 5 mg - DINAMOᵀᴹ · Mixed Models Analysis · p = 0.1394 · Mean difference (final values): 1.46 · 95% CI -0.48 to 3.41Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ vs Empagliflozin Pooled (10 mg and 25 mg) · Mixed Models Analysis · p = 0.4476 · Mean difference (final values): -0.75 · 95% CI -2.68 to 1.19Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · Mixed Models Analysis · p = 0.9789 · Mean difference (final values): 0.05 · 95% CI -3.80 to 3.90Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · Mixed Models Analysis · p = 0.5092 · Mean difference (final values): -1.35 · 95% CI -5.68 to 2.99Mean difference calculated as \[Treatment\] - Placebo.
SecondaryChange in Systolic Blood Pressure (SBP, mmHg) From Baseline to the End of 26 Weeks

Change in systolic blood pressure (SBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.

Time frame:
Baseline (Day 1) and week 26.
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change in Systolic Blood Pressure (SBP, mmHg) From Baseline to the End of 26 Weeks
millimeters of mercury (mmHg)Placebo - DINAMOᵀᴹLinagliptin 5 mg - DINAMOᵀᴹEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹPlacebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Change in Systolic Blood Pressure (SBP, mmHg) From Baseline to the End of 26 Weeks1.30 (-1.01 to 3.61)2.21 (-0.14 to 4.56)-0.12 (-2.47 to 2.24)2.63 (-4.07 to 9.34)5.16 (-0.74 to 11.06)2.63 (-4.86 to 10.12)
Statistical analysis
  • Placebo - DINAMOᵀᴹ vs Linagliptin 5 mg - DINAMOᵀᴹ · Mixed Models Analysis · p = 0.5870 · Mean difference (final values): 0.91 · 95% CI -2.40 to 4.22Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ · Mixed Models Analysis · p = 0.3967 · Mean difference (final values): -1.42 · 95% CI -4.72 to 1.88Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · Mixed Models Analysis · p = 0.5414 · Mean difference (final values): 2.53 · 95% CI -6.42 to 11.47Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · Mixed Models Analysis · p = 0.9995 · Mean difference (final values): 0.00 · 95% CI -10.13 to 10.13Mean difference calculated as \[Treatment\] - Placebo.
SecondaryChange in Diastolic Blood Pressure (DBP, mmHg) From Baseline to the End of 26 Weeks

Change in diastolic blood pressure (DBP, millimeters of mercury (mmHg)) from baseline to the end of 26 weeks. Adjusted values taken from mixed model for repeated measures (MMRM) with the fixed categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the categorical covariate age at randomisation and the continuous, fixed covariates of baseline of the response variable and baseline of the response variable-by-visit interaction. The covariate visit was treated as repeated measure with an unstructured covariance structure used to model the within-patient measurements.

Time frame:
Baseline (Day 1) and week 26.
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change in Diastolic Blood Pressure (DBP, mmHg) From Baseline to the End of 26 Weeks
millimeters of mercury (mmHg)Placebo - DINAMOᵀᴹLinagliptin 5 mg - DINAMOᵀᴹEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹPlacebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Change in Diastolic Blood Pressure (DBP, mmHg) From Baseline to the End of 26 Weeks0.76 (-1.01 to 2.53)2.26 (0.46 to 4.05)0.78 (-1.04 to 2.60)3.42 (-4.92 to 11.75)6.75 (0.14 to 13.35)-3.20 (-10.10 to 3.69)
Statistical analysis
  • Placebo - DINAMOᵀᴹ vs Linagliptin 5 mg - DINAMOᵀᴹ · Mixed Models Analysis · p = 0.2433 · Mean difference (final values): 1.50 · 95% CI -1.03 to 4.02Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ · Mixed Models Analysis · p = 0.9878 · Mean difference (final values): 0.02 · 95% CI -2.52 to 2.56Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · Mixed Models Analysis · p = 0.5670 · Mean difference (final values): 3.33 · 95% CI -9.00 to 15.65Mean difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · Mixed Models Analysis · p = 0.2348 · Mean difference (final values): -6.62 · 95% CI -18.19 to 4.95Mean difference calculated as \[Treatment\] - Placebo.
SecondaryPercentage of Patients Who Achieve HbA1c <6.5% at the End of 26 Weeks

Percentage of patients who achieve HbA1c \<6.5% at the end of 26 weeks.

Time frame:
Baseline (Day 1) and week 26.
Reported as:
Number · Percentage of subjects
Percentage of Patients Who Achieve HbA1c <6.5% at the End of 26 Weeks
Percentage of subjectsPlacebo - DINAMOᵀᴹLinagliptin 5 mg - DINAMOᵀᴹEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹPlacebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Percentage of Patients Who Achieve HbA1c <6.5% at the End of 26 Weeks9.415.421.240.016.716.7
Statistical analysis
  • Placebo - DINAMOᵀᴹ vs Linagliptin 5 mg - DINAMOᵀᴹ · Wald test · p = 0.3536 · Rate difference (percentage): 6.0 · 95% CI -7.7 to 19.9Difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ · Wald test · p = 0.0914 · Rate difference (percentage): 11.7 · 95% CI -2.4 to 26.3Difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · Fisher Exact · p = 0.5455 · Rate difference (percentage): -23.3 · 90% CI -67.9 to 27.1Difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · Fisher Exact · p = 0.5455 · Rate difference (percentage): -23.3 · 90% CI -67.9 to 27.1Difference calculated as \[Treatment\] - Placebo.
SecondaryPercentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks

Percentage of patients who achieve HbA1c \<7.0% at the end of 26 weeks.

Time frame:
Baseline (Day 1) and week 26.
Reported as:
Number · Percentage of subjects
Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks
Percentage of subjectsPlacebo - DINAMOᵀᴹLinagliptin 5 mg - DINAMOᵀᴹEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹPlacebo - DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ MonoEmpagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono
Percentage of Patients Who Achieve HbA1c <7.0% at the End of 26 Weeks24.526.934.640.016.766.7
Statistical analysis
  • Placebo - DINAMOᵀᴹ vs Linagliptin 5 mg - DINAMOᵀᴹ · Wald test · p = 0.7789 · Rate difference (percentage): 2.4 · 95% CI -15.2 to 19.5Difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ · Wald test · p = 0.2548 · Rate difference (percentage): 10.1 · 95% CI -7.7 to 28.1Difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Linagliptin 5 mg - DINAMOᵀᴹ Mono · Fisher Exact · p = 0.5455 · Rate difference (percentage): -23.3 · 90% CI -67.9 to 27.1Difference calculated as \[Treatment\] - Placebo.
  • Placebo - DINAMOᵀᴹ Mono vs Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono · Fisher Exact · p = 0.5671 · Rate difference (percentage): 26.7 · 90% CI -30.8 to 70.8Difference calculated as \[Treatment\] - Placebo.

Adverse events

Collected over Date of first study drug intake until date of last active study drug intake + residual effect period (7 days), up to 402 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono0/58 (0%)2/58 (3.4%)30/58 (51.7%)
Linagliptin 5 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono0/77 (0%)8/77 (10.4%)45/77 (58.4%)
Empagliflozin 10 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono0/74 (0%)4/74 (5.4%)47/74 (63.5%)
Empagliflozin 25 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono0/29 (0%)0/29 (0%)14/29 (48.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPlacebo Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ MonoLinagliptin 5 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 25 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono
Diabetic ketoacidosisMetabolism and nutrition disorders1/582/770/740/29
Splenic vein thrombosisBlood and lymphatic system disorders1/580/770/740/29
Pancreatitis acuteGastrointestinal disorders1/580/770/740/29
Systemic inflammatory response syndromeGeneral disorders1/580/770/740/29
HyperglycaemiaMetabolism and nutrition disorders1/581/770/740/29
Acute kidney injuryRenal and urinary disorders1/580/770/740/29
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/580/770/740/29
Hypovolaemic shockVascular disorders1/580/770/740/29
ColitisGastrointestinal disorders0/580/771/740/29
Skin candidaInfections and infestations0/580/771/740/29
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlacebo Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ MonoLinagliptin 5 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 25 mg Pooled - DINAMOᵀᴹ & DINAMOᵀᴹ Mono
HypoglycaemiaMetabolism and nutrition disorders7/5816/7712/745/29
HeadacheNervous system disorders9/5812/7712/743/29
Vitamin D deficiencyMetabolism and nutrition disorders8/586/7710/742/29
VomitingGastrointestinal disorders2/588/775/742/29
Blood ketone body increasedInvestigations2/588/775/743/29
DiarrhoeaGastrointestinal disorders5/587/773/742/29
CoughRespiratory, thoracic and mediastinal disorders5/586/774/741/29
DysmenorrhoeaReproductive system and breast disorders0/582/776/741/29
NasopharyngitisInfections and infestations3/586/773/741/29
Abdominal painGastrointestinal disorders4/585/774/741/29

Baseline characteristics

The randomised set (RS) included all randomised patients, regardless whether they took trial medication

Age, Continuous
Age, Continuous(years)Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoTotal
Mean15.3 ± 1.414.3 ± 1.714.1 ± 2.214.8 ± 1.814.4 ± 2.114.6 ± 1.813.9 ± 2.214.4 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoTotal
Female61211836318112
Male17582314563
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoTotal
Hispanic or Latino110572412665
Not Hispanic or Latino6911935337110
Unknown or Not Reported00000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoTotal
American Indian/Alaska Native01003408
Asian011152010
Black/African American54361720459
Native Hawaiian or other Pacific Islander00102003
White1131092817785
Other including mixed or missing race101042210
HbA1c
HbA1c(percentage)Placebo - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Linagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoPlacebo - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoLinagliptin 5 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoEmpagliflozin 10 mg - Empagliflozin 25 mg - DINAMOᵀᴹ & DINAMOᵀᴹ MonoTotal
Mean7.40 ± 0.778.01 ± 1.428.00 ± 1.288.14 ± 1.177.98 ± 1.097.78 ± 1.338.24 ± 1.087.94 ± 1.20
08

Study locations

83 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • CHOC Children's Hospital
    Orange, California 92868, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Rady Children's Hospital - San Diego
    San Diego, California 92123, United States
  • University of California San Francisco
    San Francisco, California 94158, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06511, United States
  • Empire Clinical Research, LLC
    Miami Lakes, Florida 33016, United States
  • Oceane7 Clinical Research
    Miami, Florida 33144, United States
  • Pediatric and Adult Research Center
    Orlando, Florida 32825, United States
  • Nemours Clinic
    Pensacola, Florida 32514, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • AdventHealth Medical Group, Pediatric Diabetes and Endocrinology at Winter Park
    Winter Park, Florida 32789, United States
  • Children's Center for Advanced Pediatrics
    Atlanta, Georgia 30329, United States
  • Atlanta Center
    Atlanta, Georgia 30331, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Novak Center for Children's Health
    Louisville, Kentucky 40202, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Joslin Diabetes Center
    Boston, Massachusetts 02215, United States
  • Integrative Biosciences Center
    Detroit, Michigan 48202, United States
  • University Of Mississippi Medical Center
    Jackson, Mississippi 39216-4505, United States
  • Children's Mercy Hospitals and Clinics
    Kansas City, Missouri 64108, United States
  • Advantage Clinical Trials
    Bronx, New York 10468, United States
  • UBMD Pediatrics
    Buffalo, New York 14203, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • The University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • University of Oklahoma
    Tulsa, Oklahoma 74135, United States
  • Penn State College of Medicine
    Hershey, Pennsylvania 17033, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Monument Health Rapid City Hospital, Inc.
    Rapid City, South Dakota 57701, United States
  • LifeDoc Research, PLLC
    Memphis, Tennessee 38119, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Office of Amir A. Hassan, MD, P.A.
    Houston, Texas 77089, United States
  • Saenz Medical Center
    La Joya, Texas 78560, United States
  • Texas Diabetes Institute
    San Antonio, Texas 78207, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Children's Hospital of Richmond at VCU
    Richmond, Virginia 23219, United States
  • Sanatorio Allende S.A.
    Nueva Córdoba, X5000JHQ, Argentina
  • Hospital de Clínicas Pte. Dr. Nicolás Avellaneda
    San Miguel de Tucumán, 4000, Argentina
  • Instituto de Estudos e Pesquisas Clínicas IEP-CE
    Fortaleza, 60160-230, Brazil
  • Fundacao de Apoio ao Ensino, Pesquisa e Assistencia do Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
    Ribeirao Preto, 14048-900, Brazil
  • University of Manitoba - Health Sciences Centre
    Winnipeg, Manitoba R3E 3P4, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • Zhengzhou Children'S Hospital
    Zhengzhou, 450017, China
  • Centro de Diabetes Cardiovascular IPS
    Barranquilla, 80020, Colombia
  • Dexa-Diab IPS
    Bogotá DC, 110221, Colombia
  • Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • Soroka Univ. Medical Center
    Beer Sheva, 84101, Israel
  • Rambam Medical Center
    Haifa, 31096, Israel
  • The Chaim Sheba Medical Center Tel HaShomer
    Ramat-Gan, 5265601, Israel
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Ajou University Hospital
    Suwon, 16499, Korea, Republic of
  • Investigación en Salud y Metabolismo S.C.
    Chihuahua, 31217, Mexico
  • CAIMED Investigacion en Salud, S.A. de C.V.
    Ciudad de México, 06760, Mexico
  • Centro de Estudios de Investigación Metabólicos y Cardiovasculares, S.C.
    Ciudad Madero, 89440, Mexico
  • Consultorio Medico
    Puebla, 72190, Mexico
  • Investigacion Medica Sonora S.C.
    Sonora, 83280, Mexico
  • Centro de Investigación Médica de Ocidente, S.C.
    Zapopan, 45116, Mexico
  • San Juan Bautista School of Medicine
    Caguas, 00726, Puerto Rico
  • Regional Clinical Hospital 'The Badge of Honor Order'
    Irkutsk, 664049, Russian Federation
  • Ivanovo Reg.Clin.Hosp.
    Ivanovo, 153040, Russian Federation
  • Rep.childrens clin.hosp.
    Izhevsk, 426009, Russian Federation
  • State Medical University, Kazan
    Kazan, 420012, Russian Federation
  • Munic. Instit. of HC "Kirov clin. hosp.#7 n.a.V.I.Urlova"
    Kirov, 610014, Russian Federation
  • Endocrinology Scientific Center, MoH and Social Development
    Moscow, 117036, Russian Federation
  • State Novosibirsk Regional Clinical Hospital
    Novosibirsk, 630091, Russian Federation
  • Fed. State Budget Educational Instit. of Higher Education "Rostov State Med. Univ." of MoH of RF
    Rostov-on-Don, 344022, Russian Federation
  • St. Petersburg State Pediatric University
    St. Petersburg, 194100, Russian Federation
  • Siberian State Med.Uni,Faculty Therapy Dep.w/ Clin.Pharmacol
    Tomsk, 634050, Russian Federation
  • Bahkir state med. Univ. of the Ministry Polyclinic Pediatric
    Ufa, 450106, Russian Federation
  • Srinagarind Hospital
    Khon Kaen, 40002, Thailand
  • Rajavithi Hospital
    Krung Thep Maha Nakhon, 10400, Thailand
  • St George's Hospital
    London, SW17 0QT, United Kingdom
  • Royal Berkshire Hospital
    Reading, RG1 5AN, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Oct 2022, 54 months.

Results were first posted in Feb 2024, 1 year 4 months after primary completion. A results delay was requested in Oct 2023.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 54 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2018
First posted
Feb 12, 2018
StartActual
Mar 20, 2018
Primary completionActual
Oct 19, 2022
CompletionActual
May 31, 2023
Results delay requested
Oct 18, 2023
Results first posted
Feb 23, 2024
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03429543
Responsible party
Sponsor
First posted
Feb 12, 2018
Start date
Mar 20, 2018
Primary completion
Oct 19, 2022
Completion
May 31, 2023
Results posted
Feb 23, 2024
Last update
Feb 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linagliptin · Empagliflozin

Start the discussion